2024 Second Quarter Earnings Conference Call August 1, 2024 2 Aaron Musgrave Vice President, Investor Relations FORWARD-LOOKING STATEMENTS 3 Safe Harbor This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. They are not guarantees or assurances of any outcomes, financial results, levels of activity, performance or achievements, and readers are cautioned not to place undue ...

业绩总结 - 公司2024年第二季度营收约为17亿欧元，调整后的EBITDA为6.69亿欧元，较去年同期增长了两位数[6] - 出货量在2024年第二季度同比增长2.7%，主要受到Purosangue、Roma Spider和296 GTS的推动[29] - 调整后的EBITDA为6.69亿欧元，边际率为39.1%[23] - 净营收按固定汇率计算增长了18.9%[38] - 车辆和零部件的营收增加归因于更丰富的产品和国家组合、个性化和更高的销量[40] 未来展望 - 公司2024年指导预期上调，预计净营收将超过6.55亿欧元，调整后的EBIT将达到27.5%的边际率[56] - 调整后的每股稀释收益预计将达到7.90欧元[63] 用户数据 - 2019年第二季度，欧洲、美洲、中国大陆、香港和台湾以及亚太其他地区的公司发货量分别为6959、7044、3392、3484、1831、1978、869、981、3172、3228、1638和1655[89] 财务状况 - 公司的净工业（负债）/现金为441百万欧元，38百万欧元，99百万欧元，207百万欧元和297百万欧元[91] - 公司的总可用流动性截至2024年6月30日为1882百万欧元，1966百万欧元，1722百万欧元，2058百万欧元和2020百万欧元[91] - 公司的总债务到期概况显示，2024年6月30日欧元1121百万，美元93百万，人民币68百万，英镑15百万和其他货币35百万[96] - 公司的净债务/调整后息税前利润比率历史趋势显示，2018年至2023年LTM为1.2x、1.0x、0.9x、0.8x、0.8x、0.7x、0.6x、0.5x、0.3x、0.3x、0.2x和0.1x[99][100] - 公司的资本支出和研发费用显示，2024年第二季度资本支出为268百万欧元，研发费用为127百万欧元[103][104]

业绩总结 - 公司第二季度2024年总收入为15.34亿美元[6] - 公司调整后的EBITDA为5.44亿美元[8] - 公司年度总收入增长13%[9] - 公司存储租金收入年度增长11%[13] - 公司2024年第三季度预期总收入约为15.5亿美元[18] 数据中心和租赁 - 公司数据中心租赁强劲，前半年总计97兆瓦[10] 股息和负债 - 公司季度股息增长10%[10] - 公司负债率为5.0倍[16] 未来展望 - 公司预计全年2024年各项指标将位于预期范围的上限[17]

Second Quarter 2024 Financial Results and Business Update August 1, 2024 Non-GAAP financial information 2 This presentation and the discussions during this conference call include certain financial measures that were not prepared in accordance with accounting principles generally accepted in the U.S. (GAAP), including adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and f ...

s � ® Incorporated Forward-Looking Statements and Non-GAAP Financial Measures The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. The company desires to take ...

业绩总结 - Bausch Health（不包括B+L）的净收入为11.9亿美元，同比增长5%，有机增长6%[13] - Bausch Health在2024年第二季度的净亏损为1美元，较去年同期27美元的净收入有所下降[147] - 2024年第二季度，Bausch Health的调整后EBITDA为11%，达到了21.41亿美元[116] 用户数据 - Xifaxan®产品线表现强劲，单位销量增长4%，总处方增长1%[51] - Relistor®受需求疲软和净定价压力影响[52] - Trulance®收入下降，受到净定价压力影响[53] 未来展望 - 2024年的重点是人才、增长、效率、创新和价值释放[107] - 在2024年，公司将专注于实现营收、调整后EBITDA和调整后经营现金流的承诺[109] 新产品和新技术研发 - 中国成功推出了Thermage® FLX产品，符合预期[67] 市场扩张和并购 - Bausch Health国际业务在2024年第二季度实现了24%的收入增长，拉美地区收入增长45%[57] 负面信息 - Bausch Health在2024年第二季度的净亏损为1美元，较去年同期27美元的净收入有所下降[147] 其他新策略和有价值的信息 - 2024年第二季度，Bausch Health的调整后EBITA为17.04亿美元，较去年同期增长12.6%[140] - Bausch Health的调整后经营活动现金流为468百万美元[156]

Moving forward Creating Shareholder Value Third Quarter 2024 Earnings Results Teleconference August 1, 2024 Moving forward Forward-Looking Statements This presentation contains "forward-looking statements" within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about earnings guidance, business outlook and investment opportunities. These forward-looking statements are based on management's expectations and assumptions as of the date of this presentatio ...

INVESTOR PRESENTATION WWW.NWPIPE.COM JULY 2024 2 FORWARD LOOKING STATEMENTS Statements in this presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on current expectations, estimates, and projections about the Company's business, management's beliefs, and assumptions made by management. These statements are not guarantees of future performance and involve ...

业绩总结 - FY2024财报显示，Astellas Pharma Inc.的营收同比增长26.2%，达到473.1亿日元[10] - 公司战略品牌总营收达到75.0亿日元，同比增长3倍[7] - 公司在2024年7月份取得了稳健的业绩，核心运营利润率为15.2%[66] 用户数据 - XTANDI在美国市场表现突出，为公司整体增长做出了贡献[6] - IZERVAY在美国市场表现超出预期，市场份额达到约35%[28] 未来展望 - 公司计划在2025年上半年开始进行zolbetuximab和化疗联合治疗的第三阶段研究[49] - 公司预计2024年和2025年的汇率为145日元和155日元，对美元和欧元的汇率变动对财务结果的影响为45.4亿日元的收入增加和11.6亿日元的核心运营利润增加[79][80] 新产品和新技术研发 - PADCEV和VEOZAH在美国和欧洲市场的销售增长强劲，预计未来将继续贡献销售额[21] - Enfortumab Vedotin (EV)在临床研究中取得了多项重要进展，包括针对不同类型癌症的多项关键研究[137] 市场扩张和并购 - 公司在2024年6月底的资产总额为3735.5亿日元，现金及现金等价物为302.9亿日元，归属于母公司所有者的总权益为1676.4亿日元，资产负债率为44.9%[83] 负面信息 - 食管和食道腺癌患者EV治疗目标为17.5%，实际结果为4.3%[101]

Strong results confirming our ability to accelerate growth, increase impact and deliver value 2Q2024 ING Group 1 August 2024 Recap of our recent Capital Markets Day ING is a highly successful bank, with a unique DNA and a strong track record Operating in attractive markets with enormous untapped potential Continuing to accelerate growth, increase impact and deliver value Aiming to be the best European bank for customers, employees, planet & society, and shareholders 2 Accelerating growth with continued stro ...